In this issue:
NRG GY018: OS & exploratory analyses of first-line pembrolizumab + chemotherapy in endometrial cancer
Adjuvant chemoradiotherapy vs. radiotherapy in cervical cancer after radical hysterectomy
PEACOCC: pembrolizumab monotherapy in clear cell gynaecological cancers
Abemaciclib + fulvestrant in HR+ endometrial cancer
Re-staging endometrial cancer according to FIGO 2023
Prognostic utility of circulating cell-free HPV DNA in cervical cancer
Cervical cancer in Aboriginal & Torres Strait Islander women
Minimally invasive surgery vs. abdominal hysterectomy in low-risk, early-stage cervical cancer
Pembrolizumab in Lynch-like vs. methylated MSI-H/dMMR endometrial cancer
RUBY: patient-reported outcomes in dMMR/MSI-H endometrial cancer
Please login below to download this issue (PDF)